Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 9/20 | 0.52 |
| ▸ | MMP13 | P45452 | 7/20 | 0.52 |
| ▸ | MMP2 | P08253 | 7/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 7/20 | 0.52 |
| ▸ | MMP3 | P08254 | 5/20 | 0.52 |
| ▸ | MMP1 | P03956 | 4/20 | 0.52 |
| ▸ | MMP7 | P09237 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797440 | 0.84 | MMP2 (0.72) | MMP9MMP13MMP2ADAMTS4MMP3 | |
| SCHEMBL6800548 | 0.81 | MMP2 (0.63) | MMP9MMP13MMP2ADAMTS4MMP3 | |
| SCHEMBL6801083 | 0.81 | MMP2 (0.63) | MMP9MMP13MMP2ADAMTS4MMP3 | |
| SCHEMBL6800772 | 0.78 | MMP2 (0.77) | MMP9MMP13MMP2ADAMTS4MMP3 | |
| SCHEMBL6799131 | 0.77 | MMP9 (0.60) | MMP9MMP13MMP2ADAMTS4MMP3 | |
| SCHEMBL30689121 | 0.77 | ADAMTS4 (0.60) | MMP9MMP13MMP2ADAMTS4MMP3 | |
| SCHEMBL6798909 | 0.76 | ADAMTS4 (0.70) | MMP9MMP13MMP2ADAMTS4MMP3 | |
| SCHEMBL5899567 | 0.76 | MMP9 (0.61) | MMP9MMP13MMP2ADAMTS4MMP3 | |
| SCHEMBL2705230 | 0.74 | ADAMTS4 (0.55) | ADAMTS4LMNASMN1; SMN2 | |
| SCHEMBL6796513 | 0.74 | MMP13 (0.50) | MMP9MMP13MMP2ADAMTS4MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977745-B1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-6087359-A | A MATRIX METALLOPROTEASE ENZYME INHIBITOR | PHARMACIA CORPORATION | 2000-07-11 | — | — | US | disclosed |
| EP-0977745-A1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998039313-A1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | MMP10, MMP1, MMP3 | MMP9 8/4885MMP13 11/4885MMP2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.